| Objective:Based on the relevant guidelines of lung cancer genetic testing both at home and abroad,the standardization of lung cancer genetic testing in Subei People’s Hospital was evaluated by investigating and analyzing the submission rate,type of specimen,proportion of specimen,positive rate of specimen,type of company,proportion of company,etc.,in order to further reflect the current situation of lung cancer genetic testing in the real world and provide certain reference for the standardization of clinical lung cancer genetic testing.Methods:During November 1,2018 and June 30,2020,428 newly diagnosed lung cancer patients were selected from the inpatient department of respiratory and critical disease medicine of Yangzhou Subei People’s Hospital.General data(including name,gender,age,smoking history,pathological type,PS score,tumor stage,genetic testing,etc.)were collected.428 newly diagnosed lung cancer patients were analyzed by using relevant statistical methods.The advantages and disadvantages of different samples and different companies were studied.Results:1.There were 9 different pathological types in 428 newly diagnosed lung cancer patients: small cell lung cancer,adenocarcinoma,squamous cell carcinoma,poorly differentiated carcinoma,mucoepidermoid carcinoma,sarcomatoid carcinoma,carcinoid,squamous cell carcinoma with small cell carcinoma,and squamous cell carcinoma with mucoepidermoid carcinoma.The pathological types accounted for15.42%,51.87%,28.27%,2.57%,0.47%,0.47%,0.23%,0.47% and 0.23%,respectively.2.428 patients with lung cancer were at a rate of 50.23%,positive rate was 53.95%.Among them,the small cell lung cancer were at a rate of 0.00%;adenocarcinoma were at a rate of 79.73%,positive rate was 59.32%,of which Ⅰ-Ⅱ adenocarcinoma were at a rate of 57.89%,Ⅲ-Ⅳ adenocarcinoma were at a rate of 81.77%;squamous cell carcinomas were at a rate of 23.97%,positive rate was 24.14%,the Ⅰ-Ⅱ squamous cell carcinomas were at a rate of 11.11%,Ⅲ-Ⅳ squamous cell carcinomas were at a rate of25.00%;The detection rate of poorly differentiated carcinoma was 54.55% and the positive rate was 50.00%;The detection rate of mucoepidermoid carcinoma was50.00%,and the positive rate was 0.00%;The detection rate of sarcomatoid carcinoma was 50.00%,and the positive rate was 0.00%;The detection rate of squamous cell carcinoma complicated with small cell carcinoma was 50.00% and the positive rate was100.00%;The detection rate of squamous cell carcinoma complicated with mucoepidermoid carcinoma was 0.00%;The detection rate of carcinoid was 0.00%.3.There were 4 types of specimens,namely tissue,peripheral blood,tissue +peripheral blood,and pleural effusion.The proportions of each specimen were 88.37%,5.58%,3.72%,2.33%,respectively,and the positive rates were 52.63%,50.00%,62.50%,and 100.00%,respectively.There was no statistically significant difference between the positive rates of each specimen(P>0.05).4.There are a total of 10 company,including Ranshi,Xinchao medcine,Kunyuan gene,Subei molecular pathology center,Anlong gene,Nanjing shihe,Lansha shengwu,Ruipu gene technology,Xiansheng detection and Guanhe medcine,the proportions of each company were 42.33%,21.86%,12.56%,6.98%,6.05%,3.72%,3.72%,1.86%,0.46%,0.46%,respectively.the positive rates were 43.96%,68.09%,66.67%,40.00%,53.85%,62.50%,62.50%,50.00%,100.00%,0.00%,respectively.The Disease Control Rates(DCR)after single first-line targeted therapy were 81.48%,96.30%,94.12%,100.00%,100.00%,100.00%,100.00%,100.00%,100.00% and unknown,respectively.Conclusion:1.Subei People’s Hospital had the highest rate of adenocarcinoma for lung cancer genetic testing,with a specific value of 79.73%.The samples were mainly tissue samples,which was consistent with the recommendations of relevant guidelines.The standard of genetic testing was ok,but the rate of adenocarcinoma did not meet the recommended standards of the guidelines,which still needed to be further standardized.2.Tissue,peripheral blood,tissue + peripheral blood and pleural effusion can all be submitted for lung cancer gene detection.However,pleural effusion tends to have a higher positive rate and is more advantageous than peripheral blood.3.In the clinical practice of Subei People’s Hospital,there are many and chaotic lung cancer gene testing companies.The positive rates and Disease Control Rates(DCR)after single first-line targeted therapy of each company are different.The positive rate and Disease Control Rate(DCR)after single first-line targeted therapy of the Xiansheng detection is the highest,while the positive rate and Disease Control Rate(DCR)of the Ranshi company is relatively low.The quality control standards of each company have not been unified yet and still need to be further standardized. |
PDF Full Text Request